Full text is available at the source.
Abstract
Resmetirom is the first approved therapeutic for metabolic dysfunction-associated steatotic liver disease (MASLD) and its severe subgroup, metabolic dysfunction-associated steatohepatitis (MASH).
- MASLD and MASH are linked to chronic overnutrition and various genetic factors.
- Physiological outcomes of these diseases include cell death in the liver, inflammation, and cirrhosis.
- Current clinical studies are exploring aspects such as placebo responses, optimal trial endpoints, and the timeline for reversing liver fibrosis.
- Therapeutic approaches include thyroid hormone receptor-β agonists, which help the liver function better in adverse metabolic conditions.
- Incretin analogues like semaglutide may enhance metabolism, promoting liver self-regulation and potentially reversing MASH symptoms.
- Combination therapies could offer additional treatment options for patients with these liver diseases.
Simplified